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The case is a 65-year-old male who has been treated for Type 2 diabetes 
mellitus (T2DM) for 26 years. He has no previous history of cerebral 
vascular accident (CVA) or coronary heart disease (CHD). He has been 
treated on insulin therapy, and recently his glucose variability became 
worse due to the irregular lifestyle. Then, diabetic treatment was changed 
to Xultophy, which consists of insulin degludec and liraglutide. 
Providing 16 units of Xultophy brought him a satisfactory daily profile of 
blood glucose, which seemed to be lower doses compared with the 
ordinary standard amount. Treatment of Xultophy seems to be effective 
and some discussion would be described from several points of view.  
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Introduction 
 The prevalence of diabetes across the world is increasing with higher speed in developed countries and also 
developing countries (1). It may cause large influences on any district and country from medical and 
economic points of view (2). As the number of diabetes increases, medical problems from diabetic 
microangiopathy and macroangiopathy increase in a variety of situations (3). Consequently, optimal therapy 
and applicable treatment for diabetes would be required. According to the current guideline of diabetes 
society, several kinds of new oral hypoglycemic agents (OHAs) and injectable agents have been introduced, 
which have been expected to reveal evident beneficial results (4).  
  As to the standard therapy of Type 2 Diabetes Mellitus (T2DM), OHAs are usually used for the first-line 
treatment. When these treatments are not so effective, insulin therapy would be applied (4). The ideal pattern 
of insulin administration was believed to provide multiple daily injections (MDI) (5). Then, the MDI has 
been standard and more prevalent in recent years. However, the new injectable agents were introduced to 
medical practice, and the clinical situation has been changing now. It may be from two agents. One is the 
clinical application of Glucagon-like Peptide-1 Receptor Agonist (GLP-1RA) (6). There are several kinds of 
GLP-1RAs and show beneficial effects for blood glucose variability. Another would be the combined factors 
of basal insulin and GLP-1RA, such as Xultophy (7). 
  There were a series of the study for Xultophy in multiple centers, that was the European Xultophy 
Treatment Retrospective Audit (EXTRA) study. Among them, a real-world evidence (RWE) study 
(EXTRA) was summarized from European countries (8). It showed beneficial efficacy for T2DM, indicating 
a satisfactory reduction of HbA1c level for half a year as minus 0.7%. Furthermore, weight reduction was 
also a significant result for half a year as minus 2.4kg. In addition to these data, another EXTRA study was 
performed with 611 patients in five countries (9). The results revealed that a substantial decrease of HbA1c 
for 6 months was minus 0.9%. Thus, it has a satisfactory effect for patients with T2DM by simple and 
convenient injection and easy continuation of treatment for a long period.  
  The authors and co-researchers have been involved in clinical matters of diabetes and Xultophy for years. 
The intake of carbohydrates causes post-prandial elevation of blood glucose. In contrast, fatty food with high 
calories does not increase blood glucose. Both of these are equivalent to calorie restriction (CR) which was 
the previous standard diet, and low carbohydrate diet (LCD) which has been recently in focus (10). There is 
various evidence of the beneficial result for LCD so far (11,12).  
  We have proposed three pattens of LCD, such as super-LCD, standard-LCD, and petite-LCD (13). They are 
simple and easy to understand and continue LCD habits. Authors have developed LCD medically and 
socially through continuous activities of the Japan LCD Promotion Association (JLCDPA) (14). In these 
healthcare and medical areas, glycemic control is needed and better control is expected.  
  In addition to the research of LCD and Meal Tolerance Test (MTT) (15), we have reported on several 
research on GLP-1RA (6,16). Furthermore, we have continued to present the reports on Xultophy (17,18). 
Both are clinically useful and their effectiveness is evaluated (19). Among various experiences, authors have 
treated an impressive T2DM male case. He has continued poor compliance with daily insulin treatment due 
to his social profession. Xultophy could contribute to improving clinical progress for its beneficial function. 
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Presentation of the Case 
Medical & Social History 
  The patient is a 65-year-old male, who has been treated with T2DM for 26 years. As to history, he did not 
have a remarkable disease or health problems including cerebral vascular accident (CVA) and coronary heart 
disease (CHD). Family history was negative for diabetes, hypertension, CVA, CHD, and so on.   
  Regarding social history, he was formerly a tennis player and has been a coach/manager of a tennis club for 
long years. He likes sports and takes part in various sports activities with many people. Such fantastic 
activity and reliable personal character have been highly evaluated, and then he was recommended to 
become a city council member in 2018. After that, he has been extremely busy and could not continue his 
regular life. He needed to give insulin shots twice a day, but it was not possible because of frequent 
unexpected official work.  
Physicals and exams 
  His physical examination showed as follows: Consciousness and vitals were unremarkable. Height 160 cm, 
weight 60 kg, BMI 23.4 kg/m2. Chest showed normal with no rale in the lung, regular rate rhythm in the 
heart, the abdomen is soft and flat and bowel sound is audible. He has no abnormality of a neurological 
condition such as diabetic neuropathy, or no signs and symptoms concerning retinopathy and nephropathy.  
  Various laboratory and physiological data in June 2018 were in the following. HbA1c 8.4%, pre-prandial 
glucose 133 mg/dL, TP 7.0 g/dL, Alb 4.5 g/dL, AST 17 U/L, ALT 13 U/L, r-GT 21 U/L, ALP 148 U/L 
(100-340), uric acid 7.3 mg/dL, BUN 16 mg/dL, Cr 0.6 mg/dL, eGFR 96 mL/min/1.73m
2
, Na 141 mEq/L, 
Cl 102 mEq/L, K 3.9 mEq/L, LDL-C 130 mg/dL, HDL 62 mg/dL, TG 89 mg/dL, Hb 14.2 g/dL, RBC 448 x 
10
6
 /μL, WBC 7200 /μL, Plt 26.5 x 10
4
 /μL, CRP 0.06 mg/dL. Chest X-P was negative, and 
electrocardiogram (ECG) was within normal limits.  
Clinical course 
  His diabetic control has been rather unstable (Figure 1). HbA1c values varied from 6.2 to 8.4% because of 
irregular lifestyle as a city council member. Previous data of blood glucose in the morning and evening were 
shown in Figure 1. Those data were compared to the changes in HbA1c values for several years. 
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  The HbA1c value was rather higher in the autumn of 2020, then diabetic treatment was changed from 
Novolin 30R twice daily to Xultophy injection once daily, which consists of insulin degludec and liraglutide. 
The actual blood glucose values are summarized in Table 1. Before starting Xultophy, Novolin 30R was 
provided twice as 21 units and 19 units, associated with unstable blood glucose for 75-195 mg/dL. Xultophy 
was begun at 8 units and was gradually increased. Just after the given doses became 16 units, the profile of 
blood glucose was normalized for 93-165 mg/dL. Glucose variability from day 8 to day 16 seemed to be 
stable (Table 1). 
Table 1: Changes in blood glucose for the case. 
Day Blood  glucose Xultophy 30R x 2 
  morning evening dose units 
-3 115 195   21 + 19 
-2 168 201   21 + 19 
-1 75 149   21 + 19 
1 158 131 8   
2 243 169 10   
3 244 302 10   
4 216 219 12   
5 209 259 12   
6 214 202 14   
7 213 214 14   
8 126 120 16   
9 93 165 16   
10 126 129 16   
11 151 138 16   
12 135 151 16   
13 149 126 16   
14 131 85 16   
15 162 - 16   
16 158 172 16   
 
Discussion   
  In this article, we report the impressive clinical progress of a 65-year-old man with T2DM. This case has 
characteristic points from medical and social points of view. As a social predisposition, he was elected to be 
a city council member of the community. Then, he could not continue regular stable life. As a result, 
diabetes control became unstable and HbA1c levels fluctuated from 6.2-8.4% (Figure 1). Novolin 30R twice 
daily could not give enough glucose control (20). Regarding this treatment way, he was formerly provided in 
a university hospital. This method was not recommended method, but he hoped to continue the protocol. 
Recently, his glucose variability became unstable, and then Xultophy was started once daily (7). 
Consequently, satisfactory control was obtained in a short period of time. These processes seemed to be very 
impressive. Various factors seem to be involved in these situations mentioned above. Here, some 
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   The first is the effectiveness of GLP-1RA. In this case, the total amount of insulin was necessary for 40 
units formerly. As Xultophy was started, satisfactory control was found at only 16 units for 8-9th days. The 
16 dose contains 16 units of long-acting insulin degludec and 0.576 mg of liraglutide of GLP-1RA. One of 
the reasons why only 16 units of Xultophy could give a satisfactory control would be the beneficial effect of 
GLP-1RAs and/or the high sensitivity of patients. 
  GLP-1RAs have been evaluated to show enough response for improving glucose variability, including 
several kinds of agents (6). They include liraglutide, exenatide, lixisenatide, dulaglutide, and others. 
Recently, a Network Meta-Analysis (NMA) for GLP-1RAs was conducted for evaluating glycemic control 
and safety outcomes (21). The research included 23209 cases with 18 GLP1-RA regimens from 54 studies, 
concluded the efficacy of glycemic control and cardiometabolic benefits and recommended patient-oriented 
clinical decisions for the consideration of comparative profiles.  
  The second is the general benefit of Xultophy. The standard method has been known to get started with 
Xultophy. When the diabetic patient was already on insulin therapy and changed to Xultophy, the initial 
doses would be 16 units according to the guideline in the usual way (7). When the case was not on insulin 
treatment and naïve situation, the initial doses would be 10 units. The author and collaborators have several 
experiences to give Xultophy in various cases. Among them, unlike European and North American 
countries, an adequate method would be to start with a small amount in Japan. Some possible reasons 
include that Japanese people are usually rather small in stature and may have a better response to insulin and 
GLP-1RA combinations (22). In our previous report, to start with 5 units and to maintain 5 units of Xultophy 
showed sufficient control of blood glucose (17). In the case of this report as well, the total amount of insulin 
was 40 units formerly, but better glucose control was obtained at only 16 units of Xultophy starting from 8-
10 units. Furthermore, Xultophy shows the beneficial points of fewer frequencies of hypoglycemia, weight 
gain, or gastrointestinal reverse effects in comparison with those of GLP-1RA alone. In this case, lower 
doses of Xultophy were enough to control blood glucose, and then it seemed to be preferable due to less 
possibility of adverse effects (23). In the future, further accumulation of various cases and their detailed 
study will be expected.    
   The third is the involvement of social history of the case, which may be important factor for the patient and 
also the adequate therapy (24). Major differences for people’s lifestyles exist between Western countries and 
Japan. In Europe and the United States, they usually have rather clear regular lives with on and off, which 
mean work hours and home hours. On the other hand, Japan has different situation from cultural aspect. 
Several professionals such as doctors, lawyers, council members and other officials often continue working 
very long hours at the expense of their private lives. The same is true for the case of this report (25). In other 
words, he has always on various jobs from morning to night. He has to treat himself by injecting twice a day. 
Due to unexpected meetings or opportunities, he could not inject insulin or keep regular lifestyle. 
Consequently, it was formerly rather difficult for him to maintain proper compliance and resilience in his 
daily life (26). 
   In summary, this case had been formerly provided insulin injections twice a day. However, due to his 
duties as a council member in the community, his daily life became extremely irregular. He could not even 
inject insulin himself in certain regular time, resulting in poor glycemic control. When the treatment was 
changed to Xultophy, glucose variability became more stable than expected with low doses by only one 
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patients. The case obtained satisfactory results from medical, psychological and social points of view. It is 
expected that medical application of Xultophy will increase and contribute the overall happiness in patients 
with T2DM.  
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